
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Impact of Medicare Advantage prescription drug plan star ratings on enrollment before and after implementation of quality-related bonus payments in 2012</dc:title>
  <dc:title>Research brief (Leonard Davis Institute of Health Economics)</dc:title>
  <dc:creator>Li, Bengxiang, author.</dc:creator>
  <dc:creator>Doshi, Jalpa A., author.</dc:creator>
  <dc:subject>Centers for Medicare &amp; Medicaid Services (U.S.)</dc:subject>
  <dc:subject>Insurance, Pharmaceutical Services -- economics</dc:subject>
  <dc:subject>Medicare Part C -- economics</dc:subject>
  <dc:subject>Medicare Part C -- statistics &amp; numerical data</dc:subject>
  <dc:subject>Quality of Health Care</dc:subject>
  <dc:subject>Reimbursement, Incentive</dc:subject>
  <dc:description>KEY FINDINGS: The five-star quality rating of Medicare Advantage Prescription Drug Plans had no direct impact on same-year enrollment. But after the introduction of a bonus payment for highly-rated plans, which had to be invested in additional benefits and /or reducing premiums, subsequent year enrollment in these plans increased.</dc:description>
  <dc:publisher>Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2016</dc:publisher>
  <dc:contributor>Leonard Davis Institute of Health Economics, issuing body.</dc:contributor>
  <dc:type>Technical Report</dc:type>
  <dc:format>Text</dc:format>
  <dc:format>Illustrations</dc:format>
  <dc:format>1 online resource (1 PDF file (2 pages))</dc:format>
  <dc:identifier>nlm:nlmuid-101691452-pdf</dc:identifier>
  <dc:identifier>101691452</dc:identifier>
  <dc:identifier>http://resource.nlm.nih.gov/101691452</dc:identifier>
  <dc:language>English</dc:language>
  <dc:coverage>United States</dc:coverage>
  <dc:rights>Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. https://creativecommons.org/licences/by/4.0</dc:rights>
</oai_dc:dc>
